Loading...
CanBas Co., Ltd.
4575.T•JPX
HealthcareBiotechnology
$1054.00
$60.00(6.04%)
CanBas Co., Ltd. (4575.T) Stock Overview
Explore CanBas Co., Ltd.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for 4575.TStats details for 4575.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 4575.TAnalyst Recommendations details for 4575.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.
CEO
Mr. Takumi Kawabe M.D., Ph.D.
Employees
11
Headquarters
2-2-1, Otemachi, Numazu
Founded
2009